Issue Highlight – July 2018

Lanza, Francesco

doi:10.1002/cyto.b.21644

Cited by 5 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also expressed by B lymphocytes isolated from the different lymphoid compartments. The molecule is up-regulated on the cell surface of activated B-lymphocytes, and is found in the cytoplasm of precursor B-cells (pro-B and pre-B lymphocytes) [8]. Sharing some general steps of the mechanistic functioning of the T cell receptor (TCR), the activation of B lymphocytes requires tight coordination, which results from the actions of multiple activating and inhibitory surface receptors.…”

Section: Cd22 Molecule and Functionmentioning

confidence: 99%

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults

Lanza

Madon

Rondoni

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

CD22 is a surface molecule expressed early during the ontogeny of B cells in the bone marrow and spleen, and can be found on B cells isolated from the different lymphoid compartments in humans. CD22 is expressed by most blasts from the majority (60–90%) of B-cell acute lymphoblastic leukemia (B-ALL). Current therapies in adults with newly diagnosed B-ALL are associated with complete remission (CR) rates of 50–90%. However, 30–60% of these patients relapse, and only 25–40% achieve disease-free survival of three years or more. Chemotherapy regimens for patients with refractory/relapsed B-ALL are associated with CR rates ranging from 31% to 44%. Novel immune-targeted therapies, such as blinatumomab and inotuzumab (a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin), provide potential means of circumventing chemo-refractory B-ALL cells through novel mechanisms of action. Eighty percent of inotuzumab-treated B-ALL patients may achieve a CR state. This review is focused on the biological and clinical activities of CD22 antibodies in B-ALL, and provides evidence about the potential role played by qualitative and quantitative analysis of the CD22 molecule on individual B-ALL blasts in predicting the depletion of leukemic cells, and, ultimately, leading to better clinical response rates.

show abstract

Section: Cd22 Molecule and Functionmentioning

confidence: 99%

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults

Lanza

Madon

Rondoni

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the INO-VATE study, a cutoff value of 90% positivity on ALL cells was not a significant determinant of InO response (79.2% versus 82.4%) [ 17 ]. However, both the percentage of positivity and the intensity of expression for CD22 antigen appear to be heterogeneous, ranging from 1% to 99% as a percentage of positive blasts, and from dim to very strong expression, as determined by the antigen expression level in single blast cells [ 24 , 25 ]. The implication of these findings may be of clinical value and could guide MRD detection [ 26 ], since it is known that immune-targeted therapies such as InO induce a rapid receptor down-modulation, forcing the flow cytometry operator to use alternative strategies to detect MRD [ 27 ].…”

Section: Immunologic Approachmentioning

confidence: 99%

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Madon

Saraceni

Lanza

2019

CHI

Self Cite

View full text Add to dashboard Cite

The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory BALL have a very poor outcome. Allogeneic hematopoietic cell transplantation (HCT) still represents the only curative approach, but is not so frequently feasible, because of patient's fitness, donor availability, and the ability to achieve a remission prior to HCT. The estimated remission rates with conventional cytotoxic agents are around 30%, but they are short-lived. These disappointing results led to the introduction of new immunologic-based treatments-blinatumomab and inotuzumab. They produced a substantial improvement in terms of response rates, with the ability, in most cases, to induce a minimal residual disease (MRD)-negative status. Similarly, T cells engineered to express a CD19-specific chimeric antigen receptor (CAR-T) have yielded sensational results among patients with relapsed/refractory BALL , with unexpectedly high MRD-negative complete remissions rates. However, the first studies looking at long-term outcomes after CART infusions told us that a significant fraction of such responses are not durable, and may benefit from a consolidation approach such as an allogeneic HCT.

show abstract

“…However, with the advent of better diagnostic techniques, the prevalence appears to be increasing. (Lanza, 2018; Rahman et al, 2022; Sun et al, 2017) It may not replace the histopathological examination, but is an important methodology which can easily and confidently provide information about the co‐ expression of different antigens and clonality assessment in NHL, especially a B cell NHL.…”

mentioning

confidence: 99%